THN102
Investigational eugeroic: a combination of modafinil and low-dose flecainide (Theranexus). Targets glial connexins (Cx30/Cx43) to amplify modafinil's wakefulness- and cognition-enhancing effect.
Pharmacology
Contents
WHAT IS THN102?
Detailed overview
THN102 is an investigational drug combination developed by Theranexus that pairs modafinil with a low dose of flecainide. Flecainide, otherwise known as a class Ic antiarrhythmic, is used here at a sub-therapeutic dose to inhibit astrocyte gap-junction connexins (Cx30 and Cx43), thereby amplifying modafinil's wake-promoting and pro-cognitive activity. In preclinical models and early human studies (sleep deprivation, Parkinson's disease excessive daytime sleepiness, narcolepsy) the combination showed a more favorable effect on vigilance, working memory and executive function than modafinil alone. It is not approved for any indication and the human data remain limited.
Mechanism
Modafinil (DAT) + glial connexin inhibition (flecainide)
Half-life
Modafinil ~12-15 h; low-dose flecainide ~12-27 h
Onset
~30-60 min (modafinil component)
Legal status
Investigational, not approved (Phase 2)
Developer
Theranexus
Receptor profile
- Dopamine transporter (DAT), modafinil componentModerate
- Astroglial connexins Cx30/Cx43 (gap junctions), low-dose flecainideModerate
- Arousal circuit (cortex, striatum, amygdala)Moderate
Safety
Side effects, stop signs, contraindications
Side effects · 6
- Headache (modafinil-type, common)
- Insomnia, sleep disturbance (especially when dosed late in the day)
- Nausea, dry mouth, decreased appetite (modafinil-type)
- Anxiety, nervousness, irritability
- Cardiac effect: flecainide is an antiarrhythmic, proarrhythmic at higher doses (the low dose used in trials was well tolerated)
- Limited human safety data: investigational combination, full side-effect spectrum unknown
Contraindications · 5
- Structural or ischemic heart disease, serious arrhythmia (because of the class Ic antiarrhythmic flecainide component)
- History of serious skin reaction (SJS, TEN, DRESS) or modafinil hypersensitivity
- Pregnancy and breastfeeding: no clinical safety data, avoid
- Drug interactions: modafinil CYP3A4 induction (contraceptives), flecainide CYP2D6 metabolism (CYP2D6 inhibitors raise its levels)
- Not an approved drug, investigational combination; not recommended for unsupervised self-treatment
Related Nootropics
Same therapeutic category
Studies
Related research and clinical findings
Efficacy of THN102 (a combination of modafinil and flecainide) on vigilance and cognition during 40-hour total sleep deprivation in healthy subjects: Glial connexins as a therapeutic target
Sauvet F, Erblang M, Gomez-Merino D, et al.
THN102 for Excessive Daytime Sleepiness Associated with Parkinson's Disease: A Phase 2a Trial
Corvol JC, Azulay JP, Bosse B, et al.
Cortico-Amygdala-Striatal Activation by Modafinil/Flecainide Combination
Vodovar D, Duchene A, Wimberley C, et al.
Impact of Astroglial Connexins on Modafinil Pharmacological Properties
Duchene A, Perier M, Zhao Y, et al.
FAQ
FAQ
Investigational eugeroic: a combination of modafinil and low-dose flecainide (Theranexus). Targets glial connexins (Cx30/Cx43) to amplify modafinil's wakefulness- and cognition-enhancing effect.
Telegram
Have a question about THN102?
Reach out to us on Telegram for a personalized stack. We'll be happy to help.
Personalized consultation
Want a detailed conversation tailored to your data?
Fill out the prep intake form (your goals, training and health data), and the advisor prepares from it to give genuinely personalized guidance.
Fill out the form~5–7 min · prep questionnaire · confidential · GDPR-compliant
Structure & chemistry
The information here is strictly for educational and scientific purposes. It does not replace medical advice or clinical consultation, and it does not encourage illegal substance or pharmaceutical use. Data is sourced. When in doubt, consult your doctor.